Developing innovative therapies that bring new hope to patients with dilated cardiomyopathy (DCM) — that is the mission of CardioGenix.
Shaping the Future of
Cardiomyopathy
Shaping the Future for Cardiomyopathy Care
Restoring Heart Muscle Power Through Science
CardioGenix advances precision medicine by uncovering the root causes of hereditary DCM through biotechnology, identifying compounds that mitigate its impact and pioneering new possibilities for treatment.
CardioGenix
DCM Research Laboratory
DCM • Cardiomyopathy • Biotech • New Hope • Medical Innovation • Genome Targeted • CardioGenix
Our Founding Story
I am Sachio Morimoto, Representative of CardioGenix LLC. For many years at Kyushu University and the International University of Health and Welfare, I have researched hereditary Dilated Cardiomyopathy (DCM). Certain forms of hereditary DCM are intractable diseases that progress due to reduced cardiac calcium sensitivity.(PDF).Without fundamental cures, many patients face the severe reality of awaiting heart transplants.Our research has demonstrated that restoring myocardial calcium sensitivity is the key to treating DCM. During my academic tenure, drug screening conducted with LTT Bio-Pharma successfully identified promising hit compounds.Determined to continue this work beyond my retirement in March 2026, I established CardioGenix to accelerate preclinical development using our proprietary data and technology.Under our mission, "Restoring heart muscle power through science," we are dedicated to providing DCM patients with new therapeutic options.We deeply appreciate your support and collaboration.
Our DCM model is the TNNT2 gene ΔK210 mutation knock-in mouse established through extensive research at Kyushu University. This model introduces the Troponin T lysine210 deletion mutation, reported in human familial DCM, into the mouse genome, serving as a vital tool for study.
This model proves that a decrease in calcium sensitivity is the decisive 'singularity' that triggers the onset of DCM. It accurately reflects human clinical symptoms—including LV dilation and sudden death—requiring careful breeding of heterozygous pairs to produce homozygous subjects for study. While this process is time-intensive, this specific model is the only way to scientifically evaluate pure calcium sensitizers in vivo. It has played a crucial role in our joint development with LTT Bio-Pharma. At CardioGenix, we leverage this proprietary technology to bring innovative treatment alternatives to DCM patients globally.